文献速递肿瘤 PET/CT核素与放射性配体治疗骨显像与常规 SPECT

68Ga-PSMA PET/CT引导下立体定向体部放疗治疗去势敏感前列腺癌寡转移骨病的结局:TROD 09-004研究

Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
PubMed 文献 · Clin Nucl Med · 2021-01-01

多中心回顾性研究评估68Ga-PSMA PET/CT检出的骨-only寡转移去势敏感前列腺癌患者接受立体定向体部放疗(SBRT)行转移导向治疗(MDT)的结局。74例患者共153个骨病灶,中位剂量20 Gy,中位随访27.3个月,2年前列腺癌特异性生存率92.0%、无进展生存率72.0%,单发寡转移和治疗后PSA反应是PCSS和PFS的显著预测因素,SBRT耐受良好。

要点

  • 68Ga-PSMA PET/CT引导SBRT治疗骨-only寡转移去势敏感前列腺癌,2年PCSS 92.0%、PFS 72.0%。
  • 单发寡转移和MDT后PSA反应是PCSS和PFS的显著预测因素。
  • 病灶水平2年局部控制率95.4%,未观察到严重晚期毒性。

核心结论

  • SBRT是68Ga-PSMA PET/CT检出5个或以下骨-only寡转移前列腺癌患者有效且耐受良好的治疗选择。

研究设计与样本

  • 多中心回顾性研究纳入74例去势敏感前列腺癌患者共153个骨病灶,均接受SBRT行MDT,中位剂量20 Gy。
  • 27例(36.5%)为同步寡转移,47例(63.5%)为异时性寡转移,所有患者68Ga-PSMA PET/CT检出转移灶≤5个。
  • 分析前列腺癌特异性生存(PCSS)和无进展生存(PFS)的预后因素,中位随访27.3个月。

主要发现

  • 2年PCSS为92.0%,2年PFS为72.0%。
  • 56例(75.7%)观察到PSA下降,48例(64.9%)达到PSA反应(MDT后PSA下降至少25%)。
  • 病灶水平2年局部控制率为95.4%。
  • 多因素分析中,单发寡转移和MDT后PSA反应是更好PCSS和PFS的显著预测因素。
  • 4例(6.5%)共10个病灶出现野内复发,中位时间为MDT完成后13.1个月,未观察到严重晚期毒性。

关键数值与推荐

  • 骨-only寡转移定义为68Ga-PSMA PET/CT检出转移灶≤5个。
  • PSA反应定义为MDT后PSA下降至少25%。
  • SBRT中位剂量为20 Gy。

临床怎么用

  • 对68Ga-PSMA PET/CT检出≤5个骨-only寡转移的去势敏感前列腺癌患者,可考虑SBRT行MDT。
  • MDT后PSA反应和单发寡转移可辅助识别预后更好的患者。

局限性

  • 回顾性研究设计。
  • 样本量74例,随访中位27.3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes of metastasis-directed treatment (MDT) using stereotactic body radiotherapy (SBRT) for bone-only oligometastasis (OM) detected with gallium prostate-specific membrane antigen (68Ga-PSMA) PET/CT in castration-sensitive prostate cancer (PC) patients. METHODS: In this multi-institutional study, clinical data of 74 PC patients with 153 bone lesions who were undergoing MDT were retrospectively evaluated. Twenty-seven patients (36.5%) had synchronous, and 47 (63.5%) had metachronous OM. All patients had PC with 5 metastases or fewer detected by 68Ga-PSMA PET/CT and treated using SBRT with a median dose of 20 Gy. The prognostic factors for PC-specific survival (PCSS) and progression-free survival (PFS) were analyzed. RESULTS: The median follow-up was 27.3 months. Patients with synchronous OM were older and received higher rates of androgen deprivation therapy after SBRT compared with patients with metachronous OM. The 2-year PCSS and PFS rates were 92.0% and 72.0%, respectively. A prostate-specific antigen (PSA) decline was observed in 56 patients (75.7%), and 48 (64.9%) had a PSA response defined as at least 25% decrease of PSA after MDT. The 2-year local control rate per lesion was 95.4%. In multivariate analysis, single OM and PSA response after MDT were significant predictors for better PCSS and PFS. In-field recurrence was observed in 4 patients (6.5%) with 10 lesions at a median of 13.1 months after MDT completion. No serious late toxicity was observed. CONCLUSIONS: We demonstrated that SBRT is an efficient and well-tolerated treatment option for PC patients with 5 bone-only oligometastases or fewer detected with 68Ga-PSMA PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Onal C, Ozyigit G, Akgun Z, et al. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study. Clin Nucl Med. 2021. PMID: 33661210. doi:10.1097/RLU.0000000000003558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。